Skip to main content
. 2021 Jul 13;12(7):696. doi: 10.1038/s41419-021-03991-3

Fig. 7. miR-301a-3p induced by ER stress mediates trastuzumab resistance in vivo and in HER2-positive GC patients.

Fig. 7

a Subcutaneous xenograft assay of NCI-N87 cells in mice with subcutaneous injection of TG or DMSO upon trastuzumab or control IgG treatment for indicated days. The volumes of the tumours were shown (n = 5 in each group). b qRT-PCR analysis of serum exosomal miR-301a-3p level from mice by different treatments n = 3. c Subcutaneous xenograft assay of NCI-N87 cells in the mice with subcutaneous injection of certain exosomes and trastuzumab or control IgG treatment for indicated days. The volumes of the tumours were shown (n = 5 in each group). d Representative ISH images of miR-301a-3p and IHC images of indicated proteins in tumour sections of different groups (n = 5 in each group). Scale bar: 50 μm. e Subcutaneous xenograft assay of NCI-N87 cells in the mice with subcutaneous injection of certain exosomes and trastuzumab or control IgG treatment for indicated days. The volumes of the tumours were shown (n = 5 in each group). f GRP78 mRNA level of HER2-positive GC patients suffering from PD or non-PD after trastuzumab therapy and miR-301a-3p expression level of HER2-positive GC patients with high or low GRP78 expression. g Representative ISH images of miR-301a-3p and IHC images of indicated proteins in tumour sections from HER2-positive GC patients suffering from PD or non-PD after trastuzumab therapy. Scale bar: 50 μm. h miR-301a-3p expression level of serum-derived exsomes in HER2-positive GC patients suffering from PD or non-PD after trastuzumab therapy. Statistical analysis was performed by Student’s t-test and one-way ANOVA, error bars indicate SD (**p < 0.01, ***p < 0.001).